Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma By Ogkologos - July 2, 2025 192 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Gastric04 study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR Black In Cancer – That Cancer Conversation October 8, 2021 NHS lung cancer patients in England to get early access to... September 9, 2021 Specific Lung Cancer Screening and Treatment Policies Urgently Needed to Address... March 23, 2022 Terminally Ill ‘Flamingo Lady’ Gets Emotional After Dying Wish Comes True September 27, 2021 Load more HOT NEWS Why haven’t we cured cancer? – That Cancer Conversation Trial Highlights Complexities of Targeted Therapy for Pancreatic Cancer EMA Recommends Extension of Therapeutic Indications for Enzalutamide For Cancer Screening, COVID-19 Pandemic Creates Obstacles, Opportunities
